$16.94
-0.20 (-1.17%)
Open$17.15
Previous Close$17.14
Day High$17.35
Day Low$16.79
52W High$28.00
52W Low$6.93
Volume—
Avg Volume1.10M
Market Cap1.08B
P/E Ratio—
EPS$-2.84
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+116.5% upside
Current
$16.94
$16.94
Target
$36.67
$36.67
$19.65
$36.67 avg
$47.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 85.08M | 76.59M | 82.32M |
| Net Income | 21.83M | 19.00M | 17.76M |
| Profit Margin | 25.7% | 24.8% | 21.6% |
| EBITDA | 33.39M | 28.41M | 32.89M |
| Free Cash Flow | 16.91M | 11.51M | 18.65M |
| Rev Growth | +15.3% | +2.7% | +8.4% |
| Debt/Equity | 0.18 | 0.16 | 0.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |